TrialSignal
Clinical trial intelligence report
A Phase I Study of mRNA Vaccine for Patients With EBV-positive Advanced Malignant Tumors
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05714748-Jul 28, 2026
NCT ID
NCT05714748
Status
ACTIVE_NOT_RECRUITING
Phase
PHASE1
Sponsor
West China Hospital
Executive brief
Investment-Ready Snapshot
A Phase I Study of mRNA Vaccine for Patients With EBV-positive Advanced Malignant Tumors is a PHASE1 clinical asset sponsored by West China Hospital in Malignant Tumors. SEO and diligence focus: EBV mRNA vaccine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05714748
Indication
Malignant Tumors
Modality
RNA therapy
Target
EBV mRNA vaccine
Intervention
EBV mRNA vaccine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.